본문으로 건너뛰기
← 뒤로

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.

Blood advances 2026

Flerlage JE, Eichenauer DA, Fuchs M, Hartmann S, Eich HT, Savage KJ, Lo AC, Skinnider B, Akhtar S, Rauf MS, Maghfoor I, Pinnix CC, Steiner RE, Milgrom SA, Vega F, Alomari M, Zhang XY, Collins GP, Advani RH, Kumar P, Dickinson MJ, Wirth A, Tsang R, Prica A, Major A, Smith SM, Hendrickson PG, Kelsey CR, Hopkins D, McKay P, Ng AK, Koenig JL, Constine LS, Casulo C, Sakthivel G, Baron JA, Plastaras JP, Roberts KB, Gao S, Al Kendi J, Al Rahbi N, Balogh AG, Levis M, Ricardi U, Sridhar A, Torka P, Specht L, De Silva R, Shah N, Pickard K, Osborne W, Blazin LJ, Henry M, Chang I, Smith CM, Halperin D, Miall F, Brady JL, Mikhaeel NG, Brennan B, Penn A, Senchenko M, Volchkov EV, Reeves M, Hoppe BS, Terezakis SA, Talaulikar D, Della Pepa R, Picardi M, Kirova Y, Fergusson P, Northend M, Hawkes EA, Lee D, Wong Doo N, Barraclough A, Opat S, Cheah CY, Salvaris R, Ku M, Hamad N, Mutsando H, Tedjaseputra A, Gilbertson M, Marconi T, Viiala N, Palese M, Shankar AG, Maurer MJ, Natkunam Y, Kelly KM, Borchmann P, Hoppe RT, Binkley MS

📝 환자 설명용 한 줄

We evaluated outcomes by management type for patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in the Global NLPHL One Working Group (GLOW) retrospective database of 2243

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 표본수 (n) 99
  • 추적기간 6.1 years

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Flerlage JE, Eichenauer DA, et al. (2026). Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.. Blood advances. https://doi.org/10.1182/bloodadvances.2026020012
MLA Flerlage JE, et al.. "Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.." Blood advances, 2026.
PMID 41979337

Abstract

We evaluated outcomes by management type for patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in the Global NLPHL One Working Group (GLOW) retrospective database of 2243 patients with stage I-IV disease diagnosed from 1992-2021 at 38 international institutions. 779 patients were stage IA with median age of 35 years (range=3-89) and median follow-up of 6.1 years. The 6-year PFS and OS were 86.3% and 97.7%, respectively. Outcomes were analyzed for two groups: complete resection and unresected disease. Patients with a complete resection and observation alone (n=99) had a 6-year PFS of 65.5% versus 90.5% for those who received RT (n=53). Patients with unresected disease (n=627; 80.5%) had a 6-year PFS of 62.0% for rituximab alone (n=31), 89.6% for RT alone (n=325), 76.8% for ABVD alone (n=40), and 94.3% for ABVD+RT (n=130). 127 patients relapsed (16.3%), of which 25 (19.7%) had transformation. Our analysis suggests 1) RT improves the PFS in patients with completely resected disease; 2) Rituximab or ABVD alone do not appear to achieve a durable response; 3) Chemotherapy was not observed to add additional PFS benefit when used in combination with RT. Thus, for stage IA NLPHL, RT alone is likely sufficient for definitive treatment.

같은 제1저자의 인용 많은 논문 (1)